Opioid Overdose Clinical Trial
Official title:
A Phase 1, Open Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adult Participants
This study will be a Phase 1, single-center, open-label, randomized cross-over study to evaluate the PK of a new AP003 device which delivers two sprays of 4 mg naloxone hydrochloride intranasally.
Based on the intended AP003 product presentation there will be two devices in each carton allowing for administration of a total of 16 mg. This study is designed for subjects to receive naloxone therapy either through the AP003 device or through the currently approved NARCAN® nasal spray (4 mg) device (per label), reference therapy. After administration of the therapy patients will be followed by a 48-hour washout period before treatment crossover. Key study parameters include safety and PK. Safety evaluations will include but not limited to complete and system directed physical examinations (including signs of nasal irritation such as erythema, edema, and erosion), administration of a Brief Smell Identification Test (B-SIT), assessments of vital signs, 12 lead electrocardiogram (ECG), continuous cardiac telemetry monitoring (CCT) , clinical laboratory tests (e.g., hematology, chemistry, urinalysis, pregnancy test), and evaluation of adverse events. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04372238 -
The Rhode Island Prescription and Illicit Drug Study
|
N/A | |
Recruiting |
NCT03924505 -
Preventing Opioid Overdose Mortality in the United States
|
N/A | |
Completed |
NCT05093309 -
Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone
|
N/A | |
Completed |
NCT05219669 -
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
|
Phase 1 | |
Completed |
NCT04317053 -
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
|
Phase 3 | |
Not yet recruiting |
NCT06466005 -
UnityPhilly Response App for Overdose Reversal
|
||
Recruiting |
NCT04815590 -
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
|
||
Active, not recruiting |
NCT05096429 -
Preventing Overdose Using Information and Data From the Environment
|
N/A | |
Suspended |
NCT05114460 -
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
|
Phase 2 | |
Recruiting |
NCT06238128 -
Opioid Rapid Response System: Naloxone Training in Communities
|
N/A | |
Completed |
NCT02662153 -
Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
|
||
Active, not recruiting |
NCT05944133 -
Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
|
||
Recruiting |
NCT05877118 -
Improving Availability of Intranasal Naloxone
|
N/A | |
Recruiting |
NCT05072249 -
European Cohort Study of the Effectiveness of Take Home Naloxone
|
||
Withdrawn |
NCT05808881 -
Clinical Outcomes From Nalmefene
|
Phase 4 | |
Not yet recruiting |
NCT01622504 -
Naloxone Nasal Spray Pharmacokinetic Study
|
Phase 1 | |
Not yet recruiting |
NCT06429436 -
Vending Machine Naloxone Distribution for Your Community (VENDY)
|
Phase 4 | |
Completed |
NCT05506267 -
Development of a Tracheal Sound Sensor
|
||
Completed |
NCT02535494 -
Risks and Benefits of Naloxone Prescribing
|
N/A | |
Not yet recruiting |
NCT06408714 -
Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose
|
Phase 3 |